Reportedly, the recombinant adenovirus serotype 3-derived protein (JO-1), which triggers the transient opening of intercellular junctions in epithelial tumors by binding to DSG2, enhanced the antitumor activity of several therapeutic monoclonal antibodies in breast cancer, lung cancer, and GC [20]. The gene discussed is DSG2; the disease is lung carcinoma.